PMID- 21750900
OWN - NLM
STAT- MEDLINE
DCOM- 20111128
LR  - 20211020
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 25
IP  - 4
DP  - 2011 Aug
TI  - Cardiac resynchronization therapy in patients with mild heart failure: a 
      systematic review and meta-analysis of randomized controlled trials.
PG  - 331-40
LID - 10.1007/s10557-011-6313-9 [doi]
AB  - OBJECTIVE: This review aims at updating the results of cardiac resynchronization 
      therapy (CRT) in mild heart failure patients, and investigating whether CRT can 
      prevent or reverse heart failure progression in an earlier stage. METHODS: 
      Randomized controlled trials of CRT in patients with New York Heart Association 
      (NYHA) Class I or II heart failure were identified. The effects of CRT on 
      worsening heart failure hospitalization, all-cause mortality, and overall adverse 
      events were meta-analyzed, and the effects of CRT on left ventricular (LV) were 
      systematically reviewed and meta-analyzed. RESULTS: Eight studies were identified 
      with a total of 4,302 patients. CRT was associated with a substantial improvement 
      in LV end-systolic volume (WMD -39, 95%CI -41.56 to -36.45). CRT also had a 
      marked effect in reducing new hospitalizations for worsening heart failure by 31% 
      (RR 0.69, 95%CI 0.60 to 0.79). In addition, CRT significantly decreased all-cause 
      mortality by 21% (RR 0.79, 95%CI 0.67 to 0.93). However, complications in 
      patients with CRT increased by 74% (RR 1.74, 95%CI 1.44 to 2.11). CONCLUSIONS: 
      This meta-analysis suggests that CRT could improve the prognosis in patients with 
      mild heart failure and ventricular dyssynchrony, but these improvements are 
      accompanied by more adverse events. Since most patients in the included trials 
      had received ICD therapy, our analysis suggests that CRT could offer an 
      additional benefit.
FAU - Tu, Ronghui
AU  - Tu R
AD  - Department of Geriatric Cardiology, First Afiliated Hospital, Guangxi Medical 
      University, 22 Shuangyong Road, 530000, Nanning, Guangxi, People's Republic of 
      China.
FAU - Zhong, Guoqiang
AU  - Zhong G
FAU - Zeng, Zhiyu
AU  - Zeng Z
FAU - Wu, Weifeng
AU  - Wu W
FAU - Wu, Hai
AU  - Wu H
FAU - Cao, Xiaoli
AU  - Cao X
FAU - Aung, Lynn Htet Htet
AU  - Aung LH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
SB  - IM
CIN - Cardiovasc Drugs Ther. 2011 Aug;25(4):281-3. PMID: 21769572
MH  - Aged
MH  - *Cardiac Resynchronization Therapy
MH  - Female
MH  - Heart Failure/mortality/*therapy
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Randomized Controlled Trials as Topic
MH  - Ventricular Remodeling
PMC - PMC3151402
EDAT- 2011/07/14 06:00
MHDA- 2011/12/13 00:00
PMCR- 2011/07/13
CRDT- 2011/07/14 06:00
PHST- 2011/07/14 06:00 [entrez]
PHST- 2011/07/14 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2011/07/13 00:00 [pmc-release]
AID - 6313 [pii]
AID - 10.1007/s10557-011-6313-9 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2011 Aug;25(4):331-40. doi: 10.1007/s10557-011-6313-9.